SCHEMBL5048628

SCHEMBL5048628

CCCCNC(=O)c1cc(-c2csc(C(=O)OCC)n2)n(Cc2ccc(OC)cc2)c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.46
ALDH1A1 P00352 3/20 0.46
KLKB1 P03952 4/20 0.43
TP53 P04637 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
KLK1 P06870 2/20 0.39
KDM4E B2RXH2 2/20 0.38
USP2 O75604 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
MAPK1 P28482 1/20 0.38
CASP1 P29466 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5046847 0.94 ALDH1A1 (0.49) HPGDALDH1A1KLKB1TP53NPC1
SCHEMBL6068954 0.93 ALDH1A1 (0.47) HPGDALDH1A1KLKB1TP53SMN1; SMN2
SCHEMBL5043761 0.89 KLKB1 (0.44) HPGDALDH1A1KLKB1TP53SMN1; SMN2
SCHEMBL5044556 0.88 KLKB1 (0.43) HPGDALDH1A1KLKB1TP53SMN1; SMN2
SCHEMBL5046032 0.87 KLKB1 (0.53) HPGDALDH1A1KLKB1TP53SMN1; SMN2
SCHEMBL5048731 0.85 ALDH1A1 (0.46) HPGDALDH1A1KLKB1TP53SMN1; SMN2
SCHEMBL5048635 0.85 MAPT (0.50) HPGDALDH1A1KLKB1TP53SMN1; SMN2
SCHEMBL5039641 0.84 ALDH1A1 (0.52) HPGDALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL5043715 0.84 HPGD (0.50) HPGDALDH1A1KLKB1TP53SMN1; SMN2
SCHEMBL5045700 0.83 KLKB1 (0.48) HPGDALDH1A1KLKB1TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R HPGD 2000/4885ALDH1A1 959/4885KLKB1 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.